Health
Canopy Biosciences develops spatial proteomics assay for COVID-19 – News-Medical.Net
Canopy Biosciences, a Bruker Company, today announced the successful development of a new assay for examining immune response to COVID-19.
Canopy Biosciences, a Bruker Company, today announced the successful development of a new assay for examining immune response to COVID-19. The assay uses high-plex spatial proteomics and is performed on Canopy’s ZellScannerONE precise spatial phenotyping instrument. ZellScannerONE enables multiplexed spatial quantification of protein biomarkers in tissue samples, as well as in suspended cells. Relative to traditional techniques, such as flow cytometry, Canopy’s ChipCytometry is able to detect and…
-
General17 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News24 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime
-
Noosa News17 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General23 hours agoCrowe toasts talkback titan for platforming ‘voiceless’